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Abstract
Background: Cerebrospinal ﬂuid (CSF) viral escape is a concern in ritonavir-boosted protease inhibitors monotherapy. The aim
was to assess HIV-RNA, biomarkers of immune activation and neurodegeneration, and atazanavir concentrations in CSF of patients
on successful long-term atazanavir/ritonavir (ATV/r) monotherapy.
Methods: This is a substudy of the multicentric, randomized, open-label, noninferiority trial monotherapy once a day with
atazanavir/ritonavir (NCT01511809), comparing the ongoing ATV/r along with 2 nucleoside retrotranscriptase inhibitors (NRTIs)
regimen to a simpliﬁed ATV/r monotherapy. Patients with plasma HIV-RNA < 50copies/mL after at least 96 study weeks were
eligible.
We assessed HIV-RNA, soluble (s)CD14, sCD163, CCL2, CXCL10, interleukin-6, and YKL40 by enzyme-linked immunosorbent
assay; neopterin, tryptophan, kynurenine, and neuroﬁlament by immunoassays; and ATV concentrations by liquid chromatography–
mass spectrometry in paired plasma and CSF samples. Variables were compared with Wilcoxon rank-sum or Fisher exact test, as
appropriate.
Results: HIV-RNA was detected in the CSF of 1/11 patients on ATV/r monotherapy (114copies/mL), without neurological
symptoms, who was successfully reintensiﬁed with his previous 2NRTIs, and in none of the 12 patients on ATV/r + 2NRTIs. CSF
biomarkers and ATV concentrations did not differ between the 2 arms.
Conclusions:CSF escape was uncommon in patients on long-term ATV/r monotherapy and was controlled with reintensiﬁcation.
Abbreviations: ART = antiretroviral therapy, ATV/r = atazanavir/ritonavir, CES-D = Center of Epidemiologic Studies Depression,
CNS = central nervous system, CSF = cerebrospinal ﬂuid, DRV/r = darunavir/ritonavir, GP = Grooved Pegboard test, IDO =
indoleamine 2,3-dioxygenase, IL = interleukin, LPV/r = lopinavir/ritonavir, MODAt = monotherapy once a day with atazanavir/
ritonavir, MRI=magnetic resonance imaging, NFL= neuroﬁlament light chain, NRTI(s)= nucleoside retrotranscriptase inhibitor(s), PF
= phonemic ﬂuency, PI/r = ritonavir-boosted protease inhibitors, RAVLT = Rey Auditory Verbal Learning Test, RAVLT rec = ReyEditor: Liang Shang.
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Simpliﬁcation of antiretroviral treatment with ritonavir-boosted
protease inhibitors (PI/r) monotherapy is a promising strategy, in
selected patients, to reduce nucleoside retrotranscriptase inhib-
itors (NRTI) side effects, pill burden, and costs and has recently
been considered in the Italian and European guidelines for
treatment of HIV infection.[1,2] Although virological efﬁcacy of
monotherapy was slightly inferior to standard regimen,[3–5]
especially in patients with low adherence,[3] low CD4+ cells
nadir,[6,7] and hepatitis C virus coinfection,[3,8] development of
resistance associated mutations was observed infrequently[9] and
prompt reintensiﬁcation with NRTI backbone at conﬁrmed viral
failure was sufﬁcient to resuppress viral replication, thus not
compromising future therapeutic options.[7–10]
A reduced efﬁcacy of PI/r monotherapy with atazanavir/
ritonavir (ATV/r), lopinavir/ritonavir (LPV/r), and darunavir/
ritonavir (DRV/r) in viral sanctuaries like the central nervous
system (CNS) is a concern. In clinical trials and isolated case
reports, in fact, virological failure tomonotherapy was associated
with onset of neurological symptoms, higher level of HIV
replication in the in the cerebrospinal ﬂuid (CSF) compared with
plasma and CSF leukocytosis.[4,6,11] Moreover, CSF viral
breakthrough in patients with suppressed systemic viral replica-
tion while on monotherapy was observed with or without
neurological symptoms.[6,7,11–13] In contrast, PI/r monotherapy
was not associated with increased neurocognitive deteriora-
tion[7,9,14–16] and CSF levels of immune activation and neuro-
degeneration biomarkers compared with standard regimen.[17]
Efﬁcacy of ATV/r monotherapy in the CNS was previously
assessed with a pilot, single arm study, ATARITMO, where CSF
replication despite suppressed plasma HIV-RNA (<50copies/
mL) was observed in 17%of patients.[11]We analyzed virological
efﬁcacy and biomarkers of immune activation and neuro-
degeneration in the CSF of patients enrolled in the randomized,
open label study monotherapy once a day with atazanavir/
ritonavir (MODAt).[8,18]2. Methods
2.1. Study design
The MODAt study is a randomized, open-label, multicenter,
noninferiority trial, comparing ATV/r (300/100mg) monother-
apy with ATV/r along with 2 NRTIs (NCT01511809). Full study
design and patient population of the MODAt trial have been
previously described.[8]
After the 96th MODAt study week, participants who did not
experience treatment failure, nor drug-related toxicities were
allowed to continue study medications and close follow up.
Patients enrolled in 1 of the 11 Italian centers participating in
the main study (center 01), with persistently undetectable plasma
HIV-RNA (<50copies/mL) after at least 96 weeks of follow-up,
including those who underwent per protocol reintensiﬁcation
for conﬁrmed viral failure, were eligible to this substudy. Those
with contraindications to magnetic resonance imaging (MRI) and
lumbar puncture were excluded.2Each enrolled patient underwent a single evaluation consisting
of an MRI, neuropsychological testing, and lumbar puncture. A
second evaluation was warranted whenever CSF escape was
detected.
The primary objective was to assess the virological efﬁcacy of
ATV/r monotherapy compared with triple therapy in the CSF
compartment. Primary endpoint was the proportion of patients,
in each treatment group, with CSF escape, deﬁned as CSF HIV-
RNA > 37copies/mL and concomitant plasma HIV-RNA < 37
copies/mL. Secondarily, we aimed to compare the level of
immune activation and neurodegeneration biomarkers and ATV
concentrations in CSF and plasma, and the neurocognitive
performance in patients of each treatment arm.
The substudy was approved by local ethical committee. Each
participant signed written informed consent to participation.2.2. Biological sample collection and biomarkers
assessment
Blood and CSF samples were collected simultaneously (±2 h
apart). Lumbar puncture was performed with atraumatic 25
gauge, Sprotte needles. Uncentrifuged CSF and plasma super-
natants, obtained after centrifugation at 1500g for 10 min, were
aliquoted and kept stored at 80°C until analysis.
HIV-1 viral load was determined by Abbott real-time
polymerase chain reaction in plasma and in the CSF (detection
limit < 37copies/mL).
The plasma and CSF concentrations of soluble (s)CD14,
CCL2, interleukin (IL)-6, CXCL10, and soluble (s)CD163 were
determined by commercial enzyme-linked immunosorbent assay
kits (R&D Systems, Minneapolis, MN), according to the
manufacturer’s instructions, at San Raffaele Scientiﬁc Institute
laboratory in Milan, Italy. Neuroﬁlament light chain (NFL) and
YKL-40 were analyzed at Sahlgrenska University Hospital,
University of Gothenburg, Sweden. NFL concentrations were
determined using a highly sensitive, 2-site enzymatic quantitative
immunoassay (lower limit of detection of 50ng/L) according to
the manufacturer’s instructions (Uman Diagnostics, Umeå,
Sweden). YKL-40 levels were measured with a commercially
available enzyme-linked immunosorbent assay according to the
manufacturer’s instructions (R&D Systems). Tryptophan, kynur-
enine, and neopterin concentrations were determined using
commercially available immunoassays at the Division of
Biological Chemistry, Biocenter Medical University Center for
Chemistry and Biomedicine, Innsbruck, Austria. Atazanavir
concentrations in plasma and CSF were determined at the Unit
of Clinical Pharmacology, Luigi Sacco University Hospital,
Milan, using liquid chromatography–mass spectrometry meth-
ods validated in agreement with the European Medicines Agency
Guidelines for Bioanalytical Method validation (lower limit of
detection 20 and 1ng/mL for plasma and CSF, respectively).2.3. Neuropsychological and radiological evaluation
Formal neuropsychological examination was administered by
trained neuropsychologists in patients with at least 96 weeks of
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revised Wechsler Adult Intelligence Scale Digit Symbol test;
learning/memory with Rey Auditory Verbal Learning Test
(RAVLT) and Rey Recall (RAVLT rec); psychomotor speed
with trail making test—part A (TMTA) and Grooved Pegboard;
executive functioning with TMT—part B (TMTB); and language
with semantic ﬂuency (SF) and phonemic ﬂuency (PF).
Age, sex, and education adjusted scores were used to obtain
normalized zeta scores for each test. A zeta score ≥1 standard
deviation below themedia of the reference population in at least 1
test of at least 2 different neurocognitive domains was considered
pathological.[19] Depressive symptoms were screened with the
Center of Epidemiologic Studies Depression (CES-D) scale.
Within 10 days prior to lumbar puncture, all patients
underwent a morphologic MRI of the brain without administra-
tion of paramagnetic contrast medium, which was reviewed by a
neuroradiologist in order to exclude contraindications to the
lumbar puncture and detect signs of neurological disease.
2.4. Statistical analysis
Results were expressed as absolute number and percentage or
median and interquartile range (IQR). Patients receiving triple
therapy after per protocol reintensiﬁcation were considered in the
triple therapy arm for analysis.
Comparisons between the 2 groups of treatmentwere calculated
with Wilcoxon rank-sum and Fisher exact test, as appropriate.
Linear correlations between variables were assessed with Spear-
man correlation coefﬁcients. All the analyses were performed with
the SAS Software, release 9.2 (SAS Institute, Cary, NC). Graphs
were obtained with Graph pad Prism 6.0 software.3. Results
3.1. Patients’ inclusion and baseline characteristics
Fourteen of 28 eligible patients randomized to ATV/r mono-
therapy and 9 of 23 to ATV/r + 2NRTIs were enrolled in the CSF
substudy. Three patients of the ATV/r monotherapy arm, who
had received per protocol reintensiﬁcation with their previous
2NRTIs at study week 8, 24, and 48, respectively, were
considered in the triple therapy arm for analysis.
Patients’ demographic and clinical characteristics at the time
of randomization for the parent MODAt study were similar
between the 2 groups of the CSF substudy (Table 1).Table 1
Clinical and demographic characteristics of patients at time of rando
ATV/r (N=11) A
Age 42 (37–50)
Male gender, n (%) 11 (100%)
Years from HIV diagnosis 6 (4–8)
Nadir CD4+, cells/mL 282 (228–363)
Pre-ART HIV-RNA, log10 c/mL 4.76 (4.05–5.60)
CD4+, cells/mL 641 (464–812)
CD8+, cells/mL 908 (665–133)
CD4+/CD8+ ratio 0.67 (0.53–0.83)
AIDS, n (%) 0
HCV infection, n (%) 1 (9%)
Duration of current ART, mo 26.3 (19.5–70.5)
Duration of HIV-RNA <50 c/mL, mo 20.7 (13.7–65.5)
Absolute numbers (%) or median (interquartile ranges) are reported. P values were calculated by Wilco
2N(t)RTI=nucleos(t)ide reverse transcriptase inhibitors, ART= antiretroviral therapy, ATV/r= atazanavir/r
33.2. Patients’ characteristics at lumbar puncture
Lumbar puncture was performed at a median (IQR) of 120 (108–
132) weeks after randomization. At this time point, all patients
were asymptomatic for neurological conditions, had undetect-
able plasma HIV-RNA (<50copies/mL), as for inclusion criteria,
and there were no differences in the CD4+ and CD8+ cell counts
between the 2 groups (Table 2).
At MRI evaluation, 4 patients in each group had scattered,
nonspeciﬁc, focal T2-weighted hyperintense, T1-weighted
isointense–hypointense microscopic subcortical lesions in the
frontal white matter. These ﬁndings were considered consistent
with microvascular lesions, within the normal range for patients’
age and of no clinical signiﬁcance.3.3. Virological efﬁcacy of ART in CSF
CSF escape was found in none of the patients receiving triple
therapy with ATV/r + 2NRTIs and in 1 of 11 (9%) on ATV/r
monotherapy, with CSFHIV-RNA of 114copies/mL. The patient
with CSF escape was a 39-year-old man, who had just recovered
from an upper respiratory tract infection at the time of lumbar
puncture. He was otherwise healthy, asymptomatic for neuro-
logical diseases and had normal MRI and CSF standard
parameters (glucose 63mg/dL, proteins 37mg/dL, and mononu-
clear cells 2/mL). He had been treated with ATV/r monotherapy
for 120 weeks, during which his plasma HIV-RNA had been
well controlled (<50copies/mL) except for 2 nonconsecutive
viral blips of 94 and 99copies/mL. His current CD4+ cells were
743/mL (41%) and had been 311/mL at nadir, his CD8+ cells
were 576/mL (31%). He had missed 1 dose of his ATV/r therapy
the day before the lumbar puncture was performed. Reintensi-
ﬁcation with his previous NRTI regimen (tenofovir and
emtricitabine) led to suppression of CSF HIV replication at
subsequent evaluation, 20 weeks afterward. Genotypic analysis
of the CSF isolate was not successful (Fig. 1).
3.4. Soluble biomarkers in CSF and plasma
CSF glucose and protein levels were within the normal range in all
CSF samples and did not differ between treatment arms. There
was a trend of higher CSF mononuclear cell counts in patients on
monotherapy compared with those on standard treatment, but,
still, they all were below the upper normal limit of 5cells/mL
(Table 2). CSF levels of neopterin, IL6, sCD14, CCL2, sCD163,mization for the MODAt study.
TV/r + 2N(t)RTIs (N=12) P All (N=23)
43 (41–47) 0.926 43 (38–47)
11 (92%) 0.999 22 (95%)
4.5 (3–6.5) 0.352 5 (4–7)
347 (315–419) 0.103 334 (268–366)
4.88 (4.58–5.32) 0.735 4.86 (4.49–5.43)
586 (485–673) 0.644 599 (467–699)
694 (529–912) 9.207 814 (551–1256)
0.72 (0.53–1.28) 0.518 0.67 (0.53–1.09)
0 – 0
3 (25%) 0.590 4 (17%)
25.0 (17.9–45.0) 0.518 25.2 (19.5–54.0)
19.3 (12.1–39.6) 0.518 19.5 (13.7–48.7)
xon rank-sum test or Fisher exact test, as appropriate.
itonavir, HCV=hepatitis C virus, MODAt=monotherapy once a day with atazanavir/ritonavir.
Table 2
Cerebrospinal ﬂuid and plasma biomarkers of viral replication, inﬂammation and neurodegeneration in patients receiving either
atazanavir/ritonavir monotherapy or atazanavir/ritonavir containing triple therapy.
CSF Plasma
ATV/r mono (n=11) ATV/r + 2NRTIs (n=12) P ATV/r mono (n=11) ATV/r + 2NRTIs (n=12) P
HIV-RNA > 50 c/mL 1 (114 copies/mL) 0 0 0
CD4+, cells/mL 691 (544–836) 680 (580–813) 0.781
CD8+, cells/mL 672 (576–1093) 769 (588–970) 0.877
CD4+/CD8+ ratio 0.93 (0.73–1.20) 0.93 (0.69–1.05) 0.689
Mononuclear, cells/mL 2 (1–4) 1 (1–2) 0.055
Glucose, mg/dL 63 (62–68) 61 (59–64) 0.138 85 (79–91) 78 (69–82) 0.029
Protein, mg/dL 36 (27–49) 34 (30–39) 0.705
CCL2, pg/mL 473 (262–880) 393 (154–614) 0.273 96.9 (1.7–179.46) 105 (1.7–170.8) 1
sCD163, ng/mL 43.79 (24.17–55.94) 32.4 (18.22–51.39) 0.496
sCD14, ng/mL 143 (80–263) 74 (0.125–206.5) 0.225 2410 (2055–3225) 1945 (1537–2107) 0.014
IL6, pg/mL 3.75 (2.66–6.38) 3.11 (2.28–6.64) 0.650 4.27 (1.76–5.49) 1.89 (1.38–3.17) 0.082
CXCL10, pg/mL 184.54 (48–270.9) 70.9 (34.54–139.09) 0.089 122.84 (79.01–164.31) 110.34 (87.04–141.59) 0.570
Neopterin, nmol/L 4.56 (4.34–4.97) 4.4 (3.93–5.81) 0.528 5.75 (4.93–12.78) 5.51 (4.88–6.80) 0.472
Tryptophan, mmol/L 2.33 (1.99–2.82) 1.62 (1.46–2.25) 0.045 77.57 (61.73–83.70) 70.47 (60.42–76.75) 0.344
Kynurenine, mmol/L 0.20 (0.20–0.24) <0.20 0.006 2.12 (1.3–2.78) 1.83 (1.21–2.17) 0.307
K/T, mmol/mmol 106 (95–118) – 27.76 (19.47–34.69) 26.70 (20.21–31.76) 0.520
YKL40, ng/mL 45.58 (30.75–68.43) 48.95 (33.55–75.22) 0.705
NFL, ng/L 263 (192–386) 294 (228–392) 0.820
ATV, ng/mL 10.9 (7–31) 14.5 (6–21) 0.847 1384 (612–2644) 891 (520–2507) 0.552
Time from last ART dose, h 13 (1–20) 1 (1–13) 0.197 18 (11–24) 24 (12–25) 0.315
Median values (interquartile ranges) are reported. P values were calculated by Wilcoxon rank-sum test (Mann–Whitney U test) or Fisher exact test, as appropriate.
ART=antiretroviral therapy, ATV= atazanavir concentration, ATV/r mono= atazanavir/ritonavir monotherapy, CSF= cerebrospinal ﬂuid, IL6= interleukin-6, K/T= kynurenine to tryptophan ratio, NFL=
neuroﬁlament, NRTIs = nucleoside reverse transcriptase inhibitors, sCD14= soluble CD14, sCD163= soluble CD163.
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groups (Table 2). Levels of tryptophan and kynurenine in the CSF
were signiﬁcantly higher in the monotherapy group compared
with the triple therapy (P=0.045 and P=0.006, respectively).
We were not able to calculate the kynurenine to tryptophan ratio,
an index of indoleamine 2,3-dioxygenase (IDO) activity, in most
of the patients receiving triple therapy, because CSF kynurenine
was undetectable.
In plasma, sCD14 was signiﬁcantly higher in the monotherapy
arm than in the triple therapy arm (P=0.014). There were noFigure 1. Plasma CD4+ cells, CSF leukocyte number, and plasma and CSF
HIV-RNA level in the patient with CSF escape. Bars above the diagram indicate
duration of antiretroviral treatments. ATV/r= ritonavir-boosted atazanavir/r,
CSF = cerebrospinal ﬂuid, FTC=emtricitabine, FU= follow-up, pl=plasma,
TDF= tenofovir.
4differences in the level of all the other biomarkers between the
2 arms (Table 2). In the patient with asymptomatic CSF escape,
CSF neopterin and CXCL10 levels were higher than the 75th
percentile of all patients (Fig. 2).
Considering all patients, levels were signiﬁcantly higher in
plasma than in CSF for IL6 (P=0.0394), sCD14 (P<0.0001),
neopterin (P=0.0002), tryptophan (P<0.0001), and kynurenineFigure 2. CSF and plasma biomarkers of immune activation and neurode-
generation in patients receiving either atazanavir/ritonavir monotherapy or
atazanavir/ritonavir containing triple therapy. Full dots represent the patient with
CSF escape. P values were calculated by Wilcoxon rank-sum test. ATV/r=
atazanavir/ritonavir, CSF = cerebrospinal ﬂuid, NRTIs=nucleoside reverse
transcriptase inhibitors.
Table 3
Neuropsychological evaluation in patients receiving either ataza-
navir/ritonavir monotherapy or atazanavir/ritonavir containing
triple therapy.
ATV/r monotherapy ATV/r + 2NRTIs P
RAVLT (Z score) 1.76 (0.73–2.63) 2.63 (1.60–3.04) 0.381
Rey rec (Z score) 1.12 (0.52–2.11) 1.87 (1.25–2.61) 0.283
TMT-A (Z score) 0.83 (0.64–1.13) 0.69 (0.57–0.89) 0.821
TMT-B (Z score) 0.62 (0.48–0.76) 0.59 (0.32–0.84) 0.314
PF (Z score) 1.93 (0.29 to 2.00) 0.55 (0.14 to 1.32) 0.314
SF (Z score) 0.83 (0.60–1.53) 0.94 (0.17–1.38) 0.705
GP-dom (Z score) 0.68 (0.52–1.01) 0.51 (0.21 to 1.67) 0.439
GP-non dom (Z score) 0.24 (0.43 to 0.55) 0.49 (0.00–1.19) 0.973
rWAIS-III DS – 1/12 (8%) –
Ferretti et al. Medicine (2016) 95:28 www.md-journal.com(P<0.0001), while CCL2 was higher in CSF (P<0.0001) and
CXCL10 was not different between the 2 compartments.
Several statistically signiﬁcant correlations were observed
between CSF but not plasma levels of different biomarkers of
immune activation. In particular, in the CSF, there was a
signiﬁcant correlation between sCD163 and sCD14 (r=0.932,
P<0.0001), sCD163 and CXCL10 (r=0.531, P=0.016),
sCD163 and CCL2 (r=0.468, P=0.037), sCD163 and IL6
(r=0.517, P=0.019), sCD14 and CXCL10 (r=0.558, P=0.01),
and sCD14 and IL6 (r=0.639, P=0.0024) (Supplementary
material, http://links.lww.com/MD/B116). CSF and plasma levels
of IL6 (r=0.657, P<0.0022) and sCD14 (r=0.542, P=0.016)
were also positively correlated.[11,24,25]
(number impaired)
Median (interquartile range) of zeta scores is reported and the number (5) of patients with impairment
is reported.
ATV/r mono=atazanavir/ritonavir monotherapy, dom=dominant hand, non dom=nondominant
hand, GP=Grooved Pegboard, NRTIs=nucleoside reverse transcriptase inhibitors, PF=phonemic
ﬂuency, RAVLT=Rey Auditory Verbal Learning Test, Rey rec=Rey recall, rWAIS-III DS= revised
Wechsler Adult Intelligence Scale Digit Symbol test, SF= semantic ﬂuency, TMT-A= trail making test
—part A, TMT-B= trail making test—part B.3.5. Pharmacokinetics
Measured ATV concentrations in plasma and CSF (Table 2) and
estimated ATV concentrations in plasma at 24h after the last
dose (P=0.47) were similar between the 2 groups. CSF ATV
concentrations were in median (IQR) 0.75% (0.68–1.39) of
plasma concentrations, without differences between the 2 arms.
CSF ATV concentrations were below the previously reported
inhibitory concentration (IC)-95% value for wild type virus (6.5
ng/mL)[20] in 7/22 (31%) patients (5 on triple therapy and 2 on
ATV/r monotherapy, including the patient with CSF escape, who
had ATV concentrations of 2.9ng/mL in CSF and 383ng/mL in
plasma). There was a correlation between plasma and CSF levels
of ATV (r=0.876, P<0.0001). Plasma, but not CSF concen-
trations of ATV were inversely correlated to the number of hours
elapsing between last dose of antiretroviral therapy (ART) and
sample collection (plasma, r=0.639, P=0.003; CSF, r=0.175,
P=0.46).3.6. Neuropsychological evaluation
Formal neuropsychological evaluation was normal in all
participants and zeta scores did not signiﬁcantly differ between
the 2 groups (Table 3). Screening for depression detected severe
symptoms in 4 patients (CES-D score≥ 23) andmild symptoms in
2 additional patients (score ≥16 and <23), without frequency or
score differences between the 2 groups.4. Discussion
In this pilot substudy of the randomized controlled trial MODAt,
CSF HIV-RNA was suppressed in all but 1 patient receiving
effective ATV/r monotherapy (9%) and in all patients receiving
effective ATV/r-based triple therapy for at least 96 weeks. CSF
escape was successfully controlled with reintensiﬁcation with
2NRTIs. CSF immune activation and neurodegeneration bio-
markers and ATV concentrations were not different in patients
receiving ATV/r monotherapy compared with those receiving
ATV/r along with 2NRTIs.
There was no evidence of neurocognitive impairment in either
of the treatment arms.
Despite differences in study design, limiting comparison among
studies, the proportion of CSF escape in the monotherapy arm of
the MODAt study was lower than that previously reported
during PI/r monotherapy with ATV/r, of 17%[11] and similar to
the frequency described in more recent studies with agents with
much higher predicted neuropenetration like DRV/r or LPV/r, of
around 10%.[6,7,14,17,21–23] This low frequency was observed
despite ATV/r concentrations in the CSF were about 1% of those5in plasma, similarly to what previously reported, and
were below the estimated IC-90 for the wild type virus in 31% of
cases.
CSF escape in patients receiving LPV/r,[6,14] ATV/r,[7,11] or
DRV/r monotherapy has previously been associated with low
CD4+ cells nadir,[6,7] poor adherence,[4,11] and discordant
patterns of resistance associated mutations in plasma and
CSF.[26–31] Moreover, in the ATARITMO study, 1 patient
presenting with high-level compartmentalized CSF replication
after 24 weeks of ATV/r monotherapy was retrospectively found
to had low level asymptomatic CSF replication, despite
suppression in plasma, at baseline CSF evaluation.[11] These
observations suggest that, during profound immunosuppression,
HIV might evolve independently within the CNS and, after
having been suppressed by effective antiretroviral treatment, it
may reemerge when treatment pressure is weakened.[32,33]
Participants to our substudy were free from some of the
above-mentioned risk factors, such as low CD4+ cell nadir
and archived antiretroviral drugs resistances in plasma, as by the
inclusion criteria to the MODAt study. In addition, they were
selected among those in whom ATV/r monotherapy had been
effective for at least 2 years, which might have contributed to the
very low frequency of CSF escape, since CSF escape often
occurred in the context of plasma failure in patients receiving
ritonavir-boosted PI monotherapy.[3,6,8,11]
The rapid suppression of CSF replication in the patient with
CSF escape after reintensiﬁcation with 2NRTI backbone suggests
that the escape was probably not sustained by a viral population
with compartmentalized resistance associated mutations. Indeed,
the patient with CSF escape had at least 2 peculiarities that could
explain the loss of virological control in the CSF compartment.
First, reduced adherence to ARTwas suspected on the basis of the
2 previous viral blips, the missed dose just before the lumbar
puncture and the low concentrations of ATV both in CSF and in
plasma. Second, the CSF escape was preceded by a mild upper
respiratory tract infection, similarly to what described in a patient
with systemic virological failure to DRV/r monotherapy,[3]
suggesting that a systemic inﬂammatory stimulus could tempo-
rarily impair the control of HIV replication.
infezione da HIV-1; 2014. http://www.salute.gov.it/imgs/C_17_pubbli
Ferretti et al. Medicine (2016) 95:28 MedicineWe did not observe increased CSF levels of biomarkers of
immune activation (sCD14, sCD163, CXCL10, IL6, neopterin,
and IDO activity), neurodegeneration (NFL), and extracellular
matrix remodeling/microglial activation (YKL-40) in patients
receiving monotherapy compared with those on triple therapy.
This was consistent with a recent observational study that
analyzed several immune activation and CNS cell damage
biomarkers, including adenosine deaminase, beta2 microglobu-
lin, S-100, neuron-speciﬁc enolase, and myelin basic protein, but
somehow in disagreement with the ﬁndings in the PROTEA
study, where CSF neopterin level increased after switch to DRV/r
monotherapy.[9,17] While in our study we only included patients
on stable and effective therapy for at least 96 weeks and in the
study published by Estebanez et al.[17] the median time on
monotherapy was of about 2 years, in the PROTEA study CSF
examination was repeated after 48 weeks. Therefore, further
studies are needed to assess whether biomarkers of immune
activation normalize in patients receiving long-term monother-
apy, after an initial increase.
In the patient with asymptomatic CSF escape, the levels of
CXCL10, which have been shown to directly correlated to CSF
viral load and cell count,[34] and of neopterin, a sensitive
inﬂammatory marker,[35] were above the 75% percentile of both
the monotherapy and whole study groups while all the other
biomarkers were included between the 25th and 75th percentiles.
This ﬁnding is consistent with previous studies that observed
increased neopterin levels in asymptomatic patients with
detectable CSF HIV RNA, despite long-term successful ART in
plasma,[35] but also suggests that there was no evidence of an
overt inﬂammatory or neurodegenerative process in the patient
with asymptomatic CSF escape.
Monotherapy was not associated with pathological neuropsy-
chological evaluation, consistently with data from larger
cohorts.[9,14,15] A beneﬁcial effect of reduction of potentially
neurotoxic antiretroviral drugs in patients receiving monother-
apy has been proposed, but we did not observe any difference
between the 2 treatment strategies.
In conclusion, CSF escape was uncommon in neuroasympto-
matic patients on long-term ATV/r monotherapy with persistent-
ly suppressed systemic viral replication. Although ATV
concentrations were low in the CSF, as expected, its efﬁcacy
was comparable to that of other, more neuropenetrating,
antiretroviral agents. Reduced adherence to ART was probably
the most important risk factor for the development of 1 case of
CSF escape, which could also have been triggered by the
concomitant systemic infection. CSF escape was not associated
with overt neurological disease and was successfully treated with
reintensiﬁcation, like observed after systemic failure to mono-
therapy regimen. Finally, ATV/rmonotherapy was not associated
with increased CSF levels of immune activation and neuro-
degeneration biomarkers.Acknowledgment
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